linvoseltamab
Regeneron
['linvoseltamab', 'mmsm', 'multiple myeloma']
the bcma/cd3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma. #asco23 #asco2023 #mmsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.